What is Guizhou Sanli Pharmaceutical Co.,Ltd's (603439.SS) StockRank?

MoatMap's StockRank for Guizhou Sanli Pharmaceutical Co.,Ltd (603439.SS) is 70/100, with a Buy signal. This is a composite score combining Quality (59), Value (21), and Momentum (78) factor ranks across MoatMap's 19,000+ stock universe.

Does Guizhou Sanli Pharmaceutical Co.,Ltd have an economic moat?

Guizhou Sanli Pharmaceutical Co.,Ltd (603439.SS) has a Quality factor score of 59/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Guizhou Sanli Pharmaceutical Co.,Ltd a buy, hold, or sell?

MoatMap's current signal for Guizhou Sanli Pharmaceutical Co.,Ltd (603439.SS) is Buy, based on a StockRank of 70/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Guizhou Sanli Pharmaceutical Co.,Ltd in?

Guizhou Sanli Pharmaceutical Co.,Ltd (603439.SS) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (China).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

603439.SS

BUYREMOVE

Guizhou Sanli Pharmaceutical Co.,Ltd · Healthcare · China · $984M · Avg Vol: $47M/d

StockRank

P/E (TTM)

122.1x

ROE

3.2%

D/E

0.5x

Dividend %

0.4%

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Guizhou Sanli is a Traditional Chinese Medicine manufacturer. It lacks alignment with our core global macro themes, has no exposure to the CDMO pricing cycle, and operates in a highly localized regulatory environment with limited international scalability.

COMPANY DESCRIPTION

Guizhou Sanli Pharmaceutical specializes in the research, development, and manufacture of proprietary Traditional Chinese Medicines (TCM), with a core focus on pediatric throat and respiratory ailments. The company's competitive moat is anchored by its exclusive, patented formulas and strong brand recognition among pediatricians and consumers in China. It operates as a highly profitable niche leader in the OTC and prescription TCM markets.

FINANCIAL SUMMARY

Year	2022	2023	2024	2025	CAGR
Revenue	178M	242M	317M	252M	12.3%
EPS	0.07	0.10	0.10	0.02	-39.2%
Shares	411M	410M	410M	409M	-0.5%
Debt	30M	82M	90M	112M	54.5%
Equity	183M	217M	226M	214M	5.3%
Op CF	43M	41M	16M	24M	-17.5%
Inv CF	-39M	-91M	-15M	-34M	—
Fin CF	-18,446	50M	-15M	-3M	—

PRICE (1M)+34.2%

SMA 50SMA 200

$2.21

RSI (14)

54.5

52W High

$2.58

From 52W High

0.9%

SCORE BREAKDOWN

Quality

ROIC

4.4%54.8

ROE

3.2%51.4

GP/Assets

41.9%80.7

Op. Margin

14.7%74.3

FCF/Assets

5.1%71.0

Piotroski

—83.5

Int. Cover

7.1x59.5

D/E Ratio

0.45x33.6

Current Ratio

1.57x26.7

Value

P/E (TTM)

122.1x7.4

EV/EBITDA

24.5x14.6

P/FCF

313.5x26.3

P/B

4.0x30.0

P/S

3.6x51.0

Div Yield

0.4%11.5

Momentum

52W High %

86%82.7

RS 6M

15%85.5

SMA 50/200

1.04x70.8

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—97.8

Q Growth

6%46.7

FUNDAMENTALS

Market Cap

$984M

P/E (Forward)

13.7x

Gross Margin

71.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 603439.SS are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
603439.SS	Guizhou Sanli Pharmaceutical Co.,Ltd(you)	$984M	70	BUY
002437.SZ	HARBIN GLORIA PHARMACEUTICALS Co., LTD	$975M	73	BUY
300705.SZ	Hunan Jiudian Pharmaceutical Co., Ltd.	$869M	70	BUY
300039.SZ	Shanghai Kaibao Pharmaceutical CO.,Ltd	$822M	68	BUY
000597.SZ	Northeast Pharmaceutical Group Co., Ltd.	$983M	64	HOLD
600195.SS	China Animal Husbandry Industry Co., Ltd.	$996M	64	HOLD
600557.SS	Jiangsu Kanion Pharmaceutical Co.,Ltd.	$1.1B	65	HOLD
002550.SZ	Changzhou Qianhong Biopharma CO.,LTD	$1.2B	66	BUY
688566.SS	Jiangsu Jibeier Pharmaceutical Co., Ltd.	$741M	65	BUY
603207.SS	Shanghai Xiao Fang Pharmaceutical Co.,Ltd.	$556M	70	BUY

Peer medians: ROE 4.8% · P/E 27.6x · Gross margin 53.0%

Guizhou Sanli Pharmaceutical Co.,Ltd (603439.SS) — Stock Score Summary

Guizhou Sanli Pharmaceutical Co.,Ltd (603439.SS) has a MoatMap StockRank of 70/100 based on Quality (59/100), Value (21/100), and Momentum (78/100) factor scores. The current signal is BUY. Guizhou Sanli is a Traditional Chinese Medicine manufacturer. It lacks alignment with our core global macro themes, has no exposure to the CDMO pricing cycle, and operates in a highly localized regulatory environment with limited international scalability.

Key Financial Metrics

Price	$2.21
Market Cap	$984M
P/E (TTM)	122.08
P/E (Forward)	13.69
Price/Book	3.97
Return on Equity	3.2%
Return on Invested Capital	4.4%
Debt/Equity	45.35
Gross Margin	71.0%
Operating Margin	14.7%
Revenue Growth	-6.6%
Dividend Yield	0.4%
Free Cash Flow	$3M

Guizhou Sanli Pharmaceutical Co.,Ltd operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is Guizhou Sanli Pharmaceutical Co.,Ltd’s (603439.SS) StockRank?: MoatMap’s StockRank for Guizhou Sanli Pharmaceutical Co.,Ltd (603439.SS) is 70/100, with a Buy signal. It is a composite of Quality (59), Value (21), and Momentum (78) factor ranks across MoatMap’s 19,000+ stock universe.
Does Guizhou Sanli Pharmaceutical Co.,Ltd have an economic moat?: Guizhou Sanli Pharmaceutical Co.,Ltd (603439.SS) has a Quality factor score of 59/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Guizhou Sanli Pharmaceutical Co.,Ltd a buy, hold, or sell?: MoatMap’s current signal for Guizhou Sanli Pharmaceutical Co.,Ltd (603439.SS) is Buy, based on a StockRank of 70/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Guizhou Sanli Pharmaceutical Co.,Ltd in?: Guizhou Sanli Pharmaceutical Co.,Ltd (603439.SS) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (China).